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ABSTRACT
Background. Persistent racial disparities in lung cancer
incidence, treatment, and survival are well documented.
Given the importance of surgical resection for lung cancer
treatment, racial disparities in surgical quality were
investigated using a statewide quality collaborative.
Methods. This retrospective study used data from the
Michigan Society of Cardiothoracic Surgeons General
Thoracic database, which includes data gathered for the
Society of Thoracic Surgeons General Thoracic Surgery
Database at 17 institutions in Michigan. Adult patients
undergoing resection for lung cancer between 2015 and
2021 were included. Propensity score-weighting methodology was used to assess differences in surgical quality,
including extent of resection, adequate lymph node evaluation, 30-day mortality, and 30-day readmission rate
between white and black patients.
Results. The cohort included 5073 patients comprising
357 (7%) black and 4716 (93%) white patients. The black
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patients had significantly higher unadjusted rates of wedge
resection than the white patients, but after propensity scoreweighting for clinical factors, wedge resection did not
differ from lobectomy (odds ratio [OR], 1.07; 95% confidence interval [CI], 0.78–1.49; P = 0.67). The black
patients had fewer lymph nodes collected (incidence rate
ratio [IRR], 0.77; 95% CI, 0.73–0.81; P \ 0.0001) and
lymph node stations sampled (IRR, 0.89; 95% CI,
0.84–0.94; P \ 0.0001). The black patients did not differ
from the white patients in terms of mortality (OR, 0.65;
95% CI, 0.19–2.34; P = 0.55) or readmission (OR, 0.79; 95
% CI, 0.49–1.27; P = 0.32). The black patients had longer
hospital stays (OR, 1.08; 95% CI, 1.02–1.14; P = 0.01).
Conclusion. In a statewide quality collaborative that
included high-volume centers, black patients received a
less extensive lymph node evaluation, with fewer nonanatomic wedge resections performed, and a more limited
lymph node evaluation with lobectomy.

Racial disparities in receipt of guideline-concordant
treatment, surgical outcomes, and survival for non-small
cell lung cancer between black and white patients have
persisted in the last two decades.1–4 Numerous studies have
demonstrated that black patients are less likely to receive
surgical resection for early-stage lung cancer.1,3,4 Findings
have shown that the lower surgical utilization rate among
black patients with early-stage lung cancer is a significant
contributor to disparities in survival.1 However, even
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among individuals receiving surgical resection, findings
have shown that black patients have higher rates of 30-day
mortality, serious complications, and readmissions.5–7
These persistent inequities in surgical care delivery for
lung cancer are multifactorial, but represent the downstream effects of differences in access to surgical care,
receipt of care at low-quality hospitals, health status and
comorbidities, social needs, patient beliefs, and provider
biases. The intersection of these differences contributes to
persistent disparities in receipt of lung cancer surgery and
poor postoperative outcomes among black patients.8–15
Despite knowledge of these racial disparities, studies
investigating disparities in the actual processes of lung
cancer care have been limited. Process measures of lung
cancer surgical care reflect all measurable steps of care
delivery and can have an impact on surgical and oncologic
outcomes. Examples include patient selection, preoperative
staging, and thoroughness of resection including lymph
node evaluation.
Prior studies assessing racial inequities in process measures have focused primarily on preoperative staging in large
claims databases, demonstrating that black patients are less
likely to receive multi-modality staging.3,16 However, a
majority of these studies used patient cohorts from more than
a decade ago, which do not reflect current practice patterns,
and did not associate these process measures with short- and
long-term outcomes or use high-quality clinical data.
Efforts to implement process and outcome measures of
surgical quality and to reduce racial disparities in lung
cancer treatment have been a priority among thoracic
surgery organizations in the last several years.17 In this
context, we sought to identify racial differences in process
and outcome measures at clinical sites participating in the
Michigan Society of Thoracic and Cardiovascular Quality
Collaborative. Since 2014, this quality collaborative has
facilitated statewide data review for 17 participating sites
to improve the quality of lung cancer care. We hypothesized that among health care systems participating in a
qualitive collaborative, racial disparities in lung cancer
quality remain.
METHODS
Data Sources
This analysis used data from 17 hospitals participating
in the Michigan Society of Thoracic and Cardiovascular
Surgeons (MSTCVS) Quality Collaborative (QC) General
Thoracic Surgery database from January 2015 to June
2021. The clinical data for the Society of Thoracic Surgeons General Thoracic Database are harvested from 17
general participant programs in Michigan by trained data

managers and submitted simultaneously to the Society of
Thoracic Surgeons General Thoracic Database (STSGTSD) and the MSTCVS-QC data warehouses.
The STS-GTSD is the largest and most robust clinical
thoracic surgical database in North America. All the
operating surgeons at each of the MSTCVS-QC sites are
board-certified in thoracic surgery, and the data from all the
participating sites are reviewed on a quarterly basis.
In this study, patient race was based on self-identification and used as a proxy measure for personally mediated
and structural racism. Individuals who self-identified as
non-Hispanic black or non-Hispanic white were included in
the analysis. We excluded individuals who self-reported as
Hispanic/Latino, Asian, or other racial or ethnic groups
(including American Indian or Alaska Native and Native
Hawaiian or Other Pacific Islander, and multiracial)
because of small sample sizes that precluded statistical
analyses. Additional patient data collected included patient
age, gender, co-morbidities, surgical history, and neoadjuvant treatment history.
Diagnosis and Procedure Identification
Patients with lung cancer were identified using the
International Classification of Diseases (ICD) ninth and
tenth revision, clinical modification (ICD-9-CM and ICD10-CM) codes using the prefixes of 162 and C34, respectively. We identified procedures for patients undergoing
surgical resection for lung cancer based on the Current
Procedural Terminology (CPT) codes for all lung cancer
resection procedures collected by the Society of Thoracic
Surgeons–General Thoracic Database.
Outcomes
Process Measures Process measures evaluate preoperative and operative phases of care. The preoperative
measures in this study included positron emission
tomography-computed
tomography
(PET-CT),
mediastinoscopy,
endobronchial
ultrasound,
brain
imaging (receipt of magnetic resonance imaging [MRI]
or computed tomography [CT]). The operative measures
included extent of resection, number of nodal stations
sampled, number of lymph nodes collected, and tumornode-metastasis (TNM) upstaging (pathologic vs
preoperative clinical staging).
Outcome Measures The outcome measures included
intensive care utilization, 30-day mortality rate, 30-day
readmission rate, 30-day postoperative complications
occurring during index hospitalization or after discharge
(atrial arrhythmia, air leak longer than 5 days, pneumonia,

Understanding Racial Differences in Lung…

discharge with a chest tube), hospital length of stay, and
discharge location.
Statistical Analysis Patient characteristics including age,
gender, tumor size, nodal involvement, percentage of
predicted preoperative forced expiratory volume in 1 s
(FEV1) and diffusion capacity for carbon monoxide
(DLCO), receipt of neoadjuvant therapy (chemotherapy
and/or radiation therapy), medical comorbidities (heart
failure, coronary artery disease, pulmonary hypertension,
cerebrovascular disease, diabetes, and dialysis dependence),
smoking status, prior cardiothoracic surgery, Zubrod/ECOG
score, extent of resection and operative time were compared
between the black and white patients using the t test, and the
chi-square test. These variables also were used as
independent variables in our propensity score model, with
race as the outcome variable. Wilcoxon tests were performed
to compare median lymph node stations sampled and lymph
nodes collected by extent of resection between the racial
groups.
Propensity Score-Weighting Propensity score-matching,
a methodology supported by the Institute of Medicine for
research on racial and ethnic disparities, was used. This
approach was used to address the possibility that the
covariate overlap between the black and white patients
might be insufficient, causing potentially biased conditional
estimates in standard regression.18
To allow for balance of covariates observed between the
racial groups, we used the Generalized Boosted Model
(GBM), an iterative algorithm forming a collection of
regression tree models to be added together to estimate the
propensity score. By including all variables potentially
associated with race and/or process measures and outcome
measures, GBM can capture main effects and interactions,
produce a smooth fit, and result in desirable estimates of a
propensity score. Inverse probability of treatment-weighting (IPTW) based on propensity score then was used to reweight black and white groups to ensure that the distribution of covariates among the two race groups was balanced.
After weighting, the balance of covariate distribution
between the black and white patients was assessed by the
absolute standardized bias (SB) and the Kolmogrov-Smirnov (KS) statistic. The balance assessment of covariate
distribution before and after weighting is presented in
Table S1 and Figs. S1 to S4. An absolute SB higher than
0.2 or a KS statistic higher than 0.1 indicate an imbalance
in the distribution of the covariates. For our data, all the
variables in the GBM model had an absolute SB lower than
0.2, a KS statistic lower than 0.1, and insignificant p values
associated with absolute SB and KS. This IPTW produced
an acceptable balance of covariate distribution between the
black and white patients.

Using the following weighted outcome comparison
models, we explored a more conservative cutoff of 0.1 for
absolute SB by including two variables, clinic node
involvement and clinical stage tumor size, with an absolute
SB above 0.1 for further adjustment. After weighting and
further adjustment to remove selection bias, the average
treatment effect provided an estimate of difference in
outcomes due to race between the white and black patients
(i.e., the comparison of outcomes had the entire population
been observed as black versus had the entire population
been observed as white). This study was deemed exempt
from the University of Michigan institutional Review
Board (HUM00207543).
RESULTS
Patient Characteristics
This study included 5073 patients who underwent
resection for lung cancer. The cohort had a mean age of
67.1 ± 9.1 years and was predominately women (n = 2758,
54.4%; Table 1). The racial composition of patients
included white patients (n = 4716, 93.0%) and black
patients (n = 357, 7.0%).
Tumor size and nodal involvement did not differ significantly between the black and white patients. The black
patients had a significantly higher percentage of predicted
FEV1 (86.3% vs. 83.5%; p \ 0.01) and a significantly
lower percentage of predicted DLCO (69.4% vs. 74.6%;
p\0.0001) than the white patients. The black patients also
had a significantly higher prevalence of hypertension
(79.3% vs. 64.3%; P \ 0.0001), congestive heart failure
(7.0% vs. 3.9%; P = 0.004), pulmonary hypertension (4.0%
vs. 1.6%; P = 0.005), cerebrovascular history (13.1% vs.
9.0%; P = 0.005), diabetes (30.3% vs. 19.1%; P \0.0001),
and dialysis dependence (2.0% vs. 0.4%; P \ 0.0001) than
the white patients. The white patients had significantly
higher rates of coronary artery disease than the black
patients (22.1% vs. 16.3%; P \ 0.01).
The racial groups did not differ in receipt of preoperative
chemotherapy or radiation, smoking status, or history of
prior cardiothoracic surgery. They did differ significantly in
functional status, with the white patients more likely to be
fully active than the black patients (61.0% vs. 55.0%; P =
0.01). The black patients had significantly shorter operative
times than the white patients (2.9 vs. 3.1 h; P = 0.003).
Unadjusted Findings
The differences in unadjusted results between the black
and white patients for all process and outcome measures
are presented in Table 2. In terms of preoperative staging,
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TABLE 1 Patient
characteristics

White
(n = 4716, 93.0%)

Black
(n = 357, 7.0%)

P value

Mean age (years)

67.3(9.1)

66.0(9.4)

0.01

Men n (%)

2176 (46.1)

139 (38.9)

0.008

Tumor size (cm) n (%)
\2

2308 (50.3)

195 (56.0)

0.08

2–3

1047 (22.8)

73 (21.0)

[ 3–5

861 (18.8)

63 (18.1)

[ 5–7

237 (5.2)

14 (4.0)

[7

133 (2.9)

3 (0.9)

N0

4213 (90.0)

327 (91.6)

N1

318 (6.8)

17 (4.8)

N2

139 (3.0)

12 (3.4)

N3

11 (0.23)

1 (0.3)

Nodal involvement
0.50

Mean FEV1 % predicted (SD)

83.5(20.03)

86.3(21.2)

0.01

Mean DLCO % predicted (SD)

74.6(20.7)

69.4(19.5)

\ 0.0001
\ 0.0001

Hypertension, n (%)

3031 (64.3)

283 (79.3)

Congestive heart failure, n (%)

1814 (3.9)

23 (7.0)

0.004

Coronary artery disease, n (%)

1041 (22.1)

58 (16.3)

0.01

Pulmonary hypertension, n (%)
Cerebrovascular history, n (%)

55 (1.6)

10 (4.0)

0.005

None

4284 (91.00)

310 (86.8)

0.005

Transient ischemic attack

171 (3.6)

13 (3.6)

Cerebrovascular accident

253 (5.4)

34 (9.5)

Diabetes, , n (%)

902 (19.1)

108 (30.3)

\ 0.0001

Dialysis, , n (%)

19 (0.4)

7 (2.0)

\ 0.0001

0 (fully active)

2871 (61.0)

194 (55.0)

1 (symptoms, fully ambulatory)

1596 (33.9)

135 (38.2)

2 (symptoms, in bed B 50%

194 (4.1)

24 (6.8)

3 (symptoms, in bed [ 50%)

40 (0.9)

0 (0)

4 (bedridden)

3 (0.1)

0 (0)

Zubrod score
0.01

FEV1, forced expiratory volume in 1 s; DLCO, diffusion capacity for carbon monoxide

the black patients were significantly more likely to receive
endobronchial ultrasound than the white patients (26.3%
vs. 20.6%; P = 0.01). The black patients did not differ
significantly from the white patients in terms of preoperative PET scan (92.7% vs. 93.4%; P = 0.60),
mediastinoscopy (7.0% vs. 9.3%; P = 0.15), or brain
imaging (25.8% vs. 29.2%; P = 0.17). They did differ
significantly in extent of resection, with the black patients
receiving wedge resections at a higher rate (22.69% vs.
16.9%; P = 0.03). The black patients had significantly
fewer mean nodal stations sampled (4.0 vs. 4.5; P \
0.0001) and lymph nodes retrieved (8.5 vs. 11.4; P \
0.0001). The black patients did not differ significantly from
the white white in terms of intensive care unit (ICU) utilization, 30-day mortality, or 30-day readmissions.

Adjusted Findings
Process Measures. The adjusted comparisons between
the black and white patients for process measures are
presented in Fig. 1. The black patients did not differ significantly from the white patients in terms of preoperative
PET-CT scan (OR, 0.97; 95% CI, 0.57–1.65; P = 0.91) or
brain imaging (OR, 1.00; 95% CI, 0.73–1.37; P = 0.99).
The black patients were less likely to receive mediastinoscopy (OR, 0.51; 95% CI, 0.29–0.88; P = 0.01) and
more likely to receive endobronchial ultrasound (OR, 1.77;
95% CI, 1.29–2.44; P = 0.0005) than the white patients.
The two races did not differ significantly in extent of
resection for wedge resection versus lobectomy (OR, 1.07;
95% CI, 0.78–1.49; P = 0.67). Given that these findings
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TABLE 2 Unadjusted process and outcome measures by racial group
Total (n = 5073) n (%)

White (n = 4716) n (%)

Black (n = 357) n (%)

P value

Preoperative PET scan

4722 (93.38)

4391 (93.4)

331 (92.7)

0.60

Medisastinoscopy

460 (9.1)

435 (9.3)

25 (7.0)

0.15

Endobronchial ultrasound

1063 (21.0)

969 (20.6)

94 (26.3)

0.01

Brain imaging

1463 (28.9)

1371 (29.2)

92 (25.8)

0.17

Pneumonectomy

95 (1.9)

91 (1.93)

4 (1.1)

Lobectomy

3777 (74.5)

3528 (74.8)

249 (69.8)

Segmentectomy

Process measures
Preoperative staging, n (%)

Extent of resection, n (%)

322 (6.4)

299 (6.3)

23 (6.4)

Wedge resection
Mean no. of nodal stations sampled (SD)

879 (17.3)
4.5 ± 2.0

798 (16.9)
4.5(2.0)

81 (22.7)
4.0(1.9)

0.03
\ 0.0001

Mean no. of lymph nodes retrieved (SD)

11.2 ± 7.8

11.4(8.0)

8.5(5.8)

\ 0.0001

Postoperative clinical upstaging, n (%)

656 (13.8)

618 (14.1)

38 (11.1)

0.13

Outcome measures
ICU utilization rate (%)

31.0

31.1

30.0

0.67

30-Day mortality rate (%)

1.3

0.9

1.3

0.45

30-Day readmission rate (%)

9.2

8.8

9.3

0.76

Atrial arrythmia

580 (11.4)

559 (11.9)

21 (5.9)

Air leak [5 days

771 (15.2)

717 (15.2)

54 (15.1)

Pneumonia

167 (3.3)

158 (3.4)

9 (2.5)

506 (10.1)

455 (9.7)

51 (14.3)

5.7 (16.4)

5.7 (15.7)

5.9 (24.16)

0.83

Home

4778 (95.1)

4447 (95.3)

331 (92.7)

0.06

Extended care
Other

235 (4.7)
11 (0.2)

211 (4.5)
9 (0.2)

24 (6.7)
2 (0.6)

Postoperative complications

Discharge with chest tube
Mean hospital stay (days)

\ 0.01
0.97
0.40
\ 0.01

Discharge locations

PET, positron emission tomography; ICU, intensive care unit

differed from the unadjusted findings, the marginal effect
of each covariate on the extent of resection was assessed. A
lower predicted DLCO, low Zubrod Score, hypertension,
smoking status and dialysis dependence were variables
associated with black patients receiving wedge resection
(Table S1).
The black patients had significantly lower rates of lymph
nodes collected (incidence rate ratio [IRR], 0.77; 95% CI,
0.73–0.81; P \ 0.0001) and nodal stations sampled (IRR,
0.89; 95% CI, 0.84–0.94; P \ 0.0001). The black patients
did not differ from the white patients in positive margin
status of resection (OR, 0.45; 95% CI, 0.19–1.04; P = 0.06)
or clinical upstaging (OR, 1.03; 95% CI, 0.63–1.67; P =
0.92). The median lymph node stations sampled varied by
extent of resection, with the white patients having a higher
median number of stations sampled for lobectomy than the
black patients (n = 5; interquartile range [IQR], 4.0–6.0 vs.
n = 4; IQR, 4.0–5.0; P \ 0.001). Similarly, the white

patients had a greater median number of lymph nodes
collected for lobectomy than the black patients (n = 11.0;
IQR, 7.0–16.0 vs. n = 9.0; IQR, 6.0–13.0; P \ 0.001)
(Table 3).
Outcome Measures
Adjusted comparisons between the black and white
patients for outcome measures are presented in Fig. 2. The
black patients did not differ significantly from the white
patients in 30-day readmissions (OR 0.79; 95% CI,
0.49–1.27; P = 0.32), 30-day mortality (OR, 0.69; 95% CI,
0.20–2.34; P = 0.55), postoperative air leak lasting longer
than 5 days (OR, 1.04; 95% CI, 0.73–1.48; P = 0.84), or
postoperative pneumonia (OR, 0.90; 95% CI, 0.41–1.99;
P = 0.80). The black patients were significantly more likely
to be discharged with a chest tube (OR, 1.54; 95% CI,
1.07–2.23; P = 0.02) and less likely to have a postoperative
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FIG. 1 Forest plot showing
adjusted odds ratio of process
measures between black and
white patients

Outcomes

Case vs. Control

OR/IRR (95% CI)

PET/CT Scan

Black vs. White

0.97 (0.57 - 1.65)

0.91

Mediastinoscopy

Black vs. White

0.51 (0.29 - 0.88)

0.01

EBUS

Black vs. White

1.77 (1.29 - 2.44)

0.0005

Brain MRI

Black vs. White

1.00 (0.73 - 1.37)

0.99

Extent of Resection

0.43

Pneumonectomy vs. Lobectomy Black vs. White

0.39 (0.11 - 1.45)

0.16

Segmentectomy vs. Lobectomy Black vs. White

0.83 (0.50 - 1.39)

0.48

Wedge vs. Lobectomy

1.07 (0.78 - 1.49)

0.67

Black vs. White

Clinical Upstaging

Black vs. White

1.03 (0.63 - 1.67)

0.92

Total Lymph Nodes Collected

Black vs. White

0.77 (0.73 - 0.81)

< 0.0001

Total Nodal Stations Sampled

Black vs. White

0.89 (0.84 - 0.94)

< 0.0001

Positive Resection

Black vs. White

0.45 (0.19 - 1.04)

0.06

← Less Outocmes
0.1

TABLE 3 Comparison of median lymph node stations sampled and
median lymph nodes collected between white and black patients
Median lymph node stations sampled
White

Black

Pneumonectomy

5.0 (3.0–6.0)

4.5 (2.5–5.0)

0.47

Lobectomy

5.0 (4.0–6.0)

4.0 (4.0–5.0)

\0.001

Segmentectomy

4.0 (3.0–6.0)

4.0 (1.0–5.0)

0.08

Wedge

3.0 (0.0–4.0)

3.0 (1.0–4.0)

0.68

P value

Median lymph nodes collected

Pneumonectomy
Lobectomy

P Value

White

Black

15.0 (10.0–22.0)

13.5 (11.5–14.0)

11.0 (7.0–16.0)

9.0 (6.0–13.0)

P value
0.50
\0.001

Segmentectomy

6.0 (4.0–11.0)

6.0 (2.0–8.0)

0.13

Wedge

4.0 (0.0–9.0)

4.0 (2.0–5.50)

0.81

atrial arrythmia (OR, 0.57; 95% CI, 0.34–0.95; P = 0.03)
than the white patients. The black patients had a significantly longer hospital stay (IRR, 1.08; 95% CI, 1.02–1.14;
P = 0.01). The two groups did not differ significantly in
terms of discharge location.
DISCUSSION
Our study had multiple principal findings related to
surgical quality indicators that improve our understanding
of black versus white racial disparities in lung cancer
surgical care. First, in the unadjusted analysis the black

0.5 1
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2 3

patients had a higher rate for receipt of wedge resection. However, with adjustment for specific clinical factors,
the racial groups did not differ significantly in receipt of
wedge versus anatomic lobectomy. Second, the black
patients had a significantly smaller lymph node station
sampling and a lower number of lymph nodes retrieved
related to higher non-anatomic wedge resections performed
and more limited lymph node evaluation with lobectomy
among the black patients. Third, short-term outcome
measures showed that the black patients had a longer stay
but not higher mortality or readmissions at our cohort of
high-volume thoracic surgery centers participating in a
statewide quality collaborative.
Prior assessments of racial differences in appropriate
lymph node evaluation have been understudied, with prior
assessments using historic patient cohorts not reflective of
current practice patterns.19 For example, Taioli et al.19
found that black patients with early-stage lung cancer in
New York between 1995 and 2012 were significantly more
likely to receive non-anatomic resection than lobectomy
but did not evaluate lymph node assessment. A prior
assessment of Medicare patients from 1992 to 2009
demonstrated that black patients were significantly more
likely to receive sub-lobar resection, to have lower rates of
lymph node evaluation, and to have fewer lymph nodes
collected.3 Osarogiabon et al.20 found similar racial disparities in lymph node evaluation.
Our findings extend these prior studies, first by
demonstrating that the racial difference in lymph node
evaluation has remained persistent over time, which may
have an impact on prognosis, adjuvant therapy, and
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FIG. 2 Forest plot showing
adjusted odds ratio of outcome
measures between black and
white patients

Case vs. Control

OR/IRR (95% CI)

P
Value

ICU Utilization

Black vs. White

0.99 (0.74 - 1.35)

0.99

30-Day Readmission

Black vs. White

0.79 (0.49 - 1.27)

0.32

30-Day Mortality

Black vs. White

0.69 (0.20 - 2.34)

0.55

Postoperative Atrial Arrhythmia Black vs. White

0.57 (0.34 - 0.95)

0.03

Air Leak > 5 Days

Black vs. White

1.04 (0.73 - 1.48)

0.84

Postoperative Pneumonia

Black vs. White

0.90 (0.41 - 1.99)

0.80

Discharge with Chest Tube

Black vs. White

1.54 (1.07 - 2.23)

0.02

Length of Stay (days)

Black vs. White

1.08 (1.02 - 1.14)

0.01

Outcomes

Discharge Location

0.08

Extended Care vs. Home

Black vs. White

1.59 (0.91 - 2.81)

0.11

Other vs. Home

Black vs. White

2.85 (0.74 - 10.92)

0.13

← Less Outcomes
0.1

survival for black patients. In our sample, we found that
this is related to both the overall higher receipt of wedge
resection among black patients and less extensive nodal
evaluation with lobectomy.
In our analysis, we demonstrated that significant differences in receipt of wedge resection between the races
became insignificant with adjustment for clinical factors.3,19 This effect in our study cohort could have resulted
from a greater prevalence of preoperative comorbidities
and lower functional status among black patients rather
than pulmonary function alone given that they had a higher
predicted FEV1 and a lower DLCO than the white patients.
However, not all clinical factors in our study found to be
associated with receipt of non-anatomic resection among
black patients are absolute contra-indications to formal
anatomic resection. For instance, the American Association
for Thoracic Surgery, in a consensus statement, determined
that frailty, low diffusion capacity, the need for supplemental oxygen, and functional status are the key
determinants of high-risk surgical candidacy for
lobectomy.21
In our cohort, the black patients did not have DLCO
below standard cutoffs for high-risk candidacy, and overall,
although their functional status was lower on the average, a
majority of black patients were fully ambulatory or active.
Additional research has demonstrated that co-morbidities
alone do not explain lower rates for receipt of surgery
among black patients.22 The absence of racial differences
in the extent of resection after adjustment for clinical
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factors in our cohort may reflect variation among participating surgeons in preoperative risk assessment or may be
secondary to the small sample size.
Ferguson et al.,23 using standardized vignette/video
pairings, demonstrated that among general thoracic surgeons, black patients were perceived as higher risk than
white patients despite the same clinical status, yet there
were no differences in recommendations for lobectomy.
This differs from a recent analysis demonstrating that white
patients were more likely to receive complex operations
after adjustment for clinical factors.24 Taken together,
these studies highlight the need for standardization of
preoperative evaluations to mitigate potential physician
bias in risk perception of black patients during surgical
evaluation for extent of resection.
Prior studies have demonstrated racial disparities in lung
cancer outcomes within large national databases. For
instance, Lam et al.5 demonstrated unchanged disparity in
mortality between black and white Medicare beneficiaries
nationwide during 2007–2016, although mortality
improved in that time for both groups. A similar disparity
has been found for hospital re-admissions, with black
patients having significantly higher re-admissions after
lung resection than white patients in a nationwide dataset.25
Our results differ by demonstrating no racial disparity in
mortality or re-admissions among patients, which may
reflect previously reported significantly better outcomes for
hospitals participating in the STS-GTSD than non-participating hospitals.26 Additionally, the clinical sites included
in the MSTCVS-QC include high-volume hospitals and
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high-volume general thoracic surgeons, which might not
reflect general practice patterns for lung cancer surgical
care. Epstein et al.27 previously found that 59.6% of white
patients undergo lung resection by a high-volume surgeon
at a high-volume center compared with 32.9% of black
patients. Additionally, black patients have been persistently
found to receive their care disproportionately in lowquality hospitals.11
In the current study, the absence of racial disparities in
outcomes likely was a function of all patients in our cohort
having equal access to high-volume cardiothoracic surgeons and high-volume hospitals.28,29 Thus, racial
disparities in outcomes might be mitigated when black
patients have access to the same high-quality surgical care
as white patients.
Our findings have important implications for future
work regarding the evaluation of racial disparities in the
quality of lung cancer outcomes. First, racial disparities in
outcomes such as mortality and readmissions were not
present among the patients receiving resection by cardiothoracic surgeons in a statewide quality collaborative. This
supports initiatives to improve equal access to high-quality
surgical services, which requires targeted efforts to address
well-documented barriers to care for certain racial and
ethnic groups as well as referral patterns for surgical services. It also highlights the importance of quality
collaboratives as a mechanism for regular review of outcomes and dissemination of best practice among surgical
practices.
Second, the lack of significance in racial disparity and the
extent of lung resection after adjustment suggests the existence of modifiable operative risk factors more prevalent
among black patients that could be targeted to increase
receipt of lobectomy. These risk factors include medical
optimization of co-morbidities and functional status, all of
which have been identified previously within the STS-GTSD
as predictors of perioperative risk for lobectomy.30 The
higher rate of these factors among the black patients in our
cohort may be associated with the higher unadjusted receipt
of sub-lobar resection. Preoperative medical optimization
and pre-habilitation programming may be of particular
benefit to black patients.31,32 If black patients are less likely
to receive formal anatomic resection secondary to higherrisk candidacy, then surgeons should consider referral to
target programming that potentially mitigates risk and
increases the likelihood of receipt of anatomic resection.

does not reflect known practice patterns of the variation in
surgeon specialties and operations for lung cancer resection. This may contribute to an underestimation of the true
racial disparities in Michigan given that nationally, a significant proportion of operations may be performed by
general surgeons. Furthermore, the MSTCVS database
does not differentiate between cardiothoracic surgeons and
general thoracic surgeons.
Second, the racial demographics of our patient cohort
varied from the known prevalence of lung cancer among
black patients in the state of Michigan. This is likely
multifactorial but likely is affected by disparities in receipt
of surgery among black patients, racial disparities in
resectable disease, and the fact that our participating sites
do not fully capture health care systems in which potentially disproportionate numbers of black patients receive
their care. Furthermore, the possible concentration of black
patients within a small subset of hospitals belonging to the
quality collaborative might reflect differences in care, such
as the differences in approach to mediastinal staging
between endobronchial ultrasound and mediastinoscopy.
Future assessment of practice-level variation is needed to
evaluate how hospital or health care system differences
contribute to disparities. Additionally, it has been previously noted that the STS-GTSD-participating sites in
Michigan do not represent all hospitals performing at least
one lobectomy in 2013.26 Although participation in the
MSTCVS General Thoracic Surgery QC has increased
substantially over time, the state likely still has practitioners and hospitals that do not report data to the STSGTSD. This is particularly important in the context of
evaluation of racial disparities given that hospitals in the
United States remain highly racially segregated, with the
resulting probability that not all racial groups were equally
represented in our cohort.26,33
Third, our study did not include an analysis of differences in operative technique as a mechanism for potential
racial disparities, particularly a nodal evaluation due to
limited variables. Given ongoing research into how open,
video-assisted thoracoscopic surgery (VATS) and robotic
surgery vary in lymph node evaluation, this represents a
potentially unmeasured confounder in our assessment.
Future research should assess whether variation in
approach may contribute to the disparities in lymph node
evaluation found in this study.
CONCLUSION

STUDY LIMITATIONS
This study should be interpreted in light of several
limitations. First, all the patients in our study received
operations by practicing cardiothoracic surgeons, which

In this assessment of a statewide quality collaborative,
significant racial disparities between black and white
patients were found in lymph node evaluation, hospital
length of stay, and unadjusted extent of resection. These
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findings demonstrate the need for standardization of preoperative assessment and medical management to improve
receipt of anatomic resections by black patients.
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supplementary material available at https://doi.org/10.1245/s10434022-12435-x.
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